• Home/
  • Press Releases/
  • Global Treprostinil Drugs Market to Augment at a CAGR of 0.7% by 2025 as it Promises Elimination of Side Effects

Los Angeles, December 26, 2019 -  Treprostinil is rising in demand as it is widely used for the treatment of pulmonary arterial hypertension (PAH). QY Research has recently published a report that explains the market growth of treprostinil drugs. Report titled “Global Treprostinil Drugs Market Insights, Forecast to 2025” was worth US$ 1219 mn during 2018 and is expected to reach US$ 1284.4 mn by the end of 2025, registering a CAGR of 0.7% during the forecast period.

Global Treprostinil Drugs Market.jpg


Get PDF sample copy of the report at: https://www.qyresearch.com/sample-form/form/1357655/global-treprostinil-drugs-market


Ability to Widen the Arteries in Patients Suffering from PAH to Augment the Market Growth


The market is driven by the growing demand for reducing the blood clots in the platelets of a patient. It is extensively used to treat PAH and to improve the ability to exercise. Its ability to be consumed in oral, inhalation, or injection form makes it more desirable. It helps in vasodilating pulmonary and systematic arterial beds and inhibiting platelet aggregation. It also aids in inhibiting inflammatory cytokine. It is a synthetic analogue of prostacyclin, which makes it ideal for binding prostacyclin receptors. Thus, it is prescribed by various doctors across the globe.


It has the ability to be absorbed rapidly and completely after subcutaneous infusion. It possess stability at room temperature and has neutral pH thus, it can be given in various doses and by various means. It is ideal for patients consuming epoprostenol for pulmonary arterial hypertension and want to alter to another drug because this drug eliminates the rate of clinical deterioration.


Importance of Medication Adherence to Boost the Hospital Segment


As the usage of this drug needs to be administered by doctors, hospital segment is likely to flourish during the forecast period. Hospital segment during 2018 accounted for 52% of the proportion.


The proportion of sales of Remodulin was 60% and of Tyvaso was 23% during 2018. Therefore Remodulin is expected rise in the coming years.


North America to Flourish with a Strong Healthcare Sector


North America is expected to lead the global market as it has strong players and a robust healthcare infrastructure. This region is also technologically advanced, which means it has one of the leading healthcare system in the world. North America consumed 92% of the global share during 2018.


United Therapeutics and Corsair Pharma recently entered into a strategic collaboration and license agreement to develop novel Treprostinil prodrugs. United Therapeutics has made a minor equity investment in Corsair to acquire shares of Corsair.


The key players operating in the global Treprostinil drug market are United Therapeutics, Novartis, and Teva.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.

Contact US

QY Research, INC.

17890 Castleton, Suite 218,

Los Angeles, CA – 91748

USA: +1 626 428 8800

China: +86 1082 945 717

Japan: +81 9038 009 273

India: +91 9766 478 224

Emails – enquiry@qyresearch.com

Web – www.qyresearch.com 

©2007-2026 QY Research All Rights Reserved.